Hoth Therapeutics Stock Forecast, Price & News

Hoth Therapeutics (NASDAQ:HOTH) Frequently Asked Questions

How has Hoth Therapeutics' stock been impacted by COVID-19?

Hoth Therapeutics' stock was trading at $3.84 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HOTH shares have decreased by 78.9% and is now trading at $0.8110.
View which stocks have been most impacted by COVID-19.

Are investors shorting Hoth Therapeutics?

Hoth Therapeutics saw a increase in short interest in November. As of November 15th, there was short interest totaling 236,400 shares, an increase of 34.2% from the October 31st total of 176,100 shares. Based on an average trading volume of 328,500 shares, the short-interest ratio is currently 0.7 days. Approximately 1.3% of the shares of the company are sold short.
View Hoth Therapeutics' Short Interest.

When is Hoth Therapeutics' next earnings date?

Hoth Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Hoth Therapeutics.

How were Hoth Therapeutics' earnings last quarter?

Hoth Therapeutics, Inc. (NASDAQ:HOTH) announced its earnings results on Wednesday, November, 10th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.01.
View Hoth Therapeutics' earnings history.

Who are Hoth Therapeutics' key executives?

Hoth Therapeutics' management team includes the following people:

• Robbie Knie, Chairman, President & Chief Executive Officer
• Hayley Springer, Vice President-Operations
• David S. Briones, Chief Financial & Accounting Officer
• Stefanie Johns, Chief Scientific Officer
• MaryBeth Jones, Director-Project Management

Who are some of Hoth Therapeutics' key competitors?

Some companies that are related to Hoth Therapeutics include Capricor Therapeutics (CAPR), Biophytis (BPTS), Edesa Biotech (EDSA), Orgenesis (ORGS), Longboard Pharmaceuticals (LBPH), Osmotica Pharmaceuticals (OSMT), Neptune Wellness Solutions (NEPT), Emmaus Life Sciences (EMMA), Catabasis Pharmaceuticals (ATXS), AcelRx Pharmaceuticals (ACRX), Lotus Pharmaceuticals (LTUS), IntelGenx Technologies (IGXT), Lannett (LCI), Rezolute (RZLT) and Helix BioPharma (HBPCF).
View all of HOTH's competitors.

What other stocks do shareholders of Hoth Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Citius Pharmaceuticals (CTXR), Ocugen (OCGN), Fulcrum Therapeutics (FULC), Heat Biologics (HTBX), Tonix Pharmaceuticals (TNXP), AIM ImmunoTech (AIM), Aytu Biopharma (AYTU), Gilead Sciences (GILD), iBio (IBIO) and Nabriva Therapeutics (NBRV).

When did Hoth Therapeutics IPO?

(HOTH) raised $8 million in an initial public offering on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

What is Hoth Therapeutics' stock symbol?

Hoth Therapeutics trades on the NASDAQ under the ticker symbol "HOTH."

Who are Hoth Therapeutics' major shareholders?

Hoth Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.50%) and Bank of New York Mellon Corp (0.16%).
View institutional ownership trends for Hoth Therapeutics.

Which institutional investors are buying Hoth Therapeutics stock?

HOTH stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Hoth Therapeutics or or view top insider-buying stocks.

How do I buy shares of Hoth Therapeutics?

Shares of HOTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hoth Therapeutics' stock price today?

One share of HOTH stock can currently be purchased for approximately $0.81.

How much money does Hoth Therapeutics make?

Hoth Therapeutics has a market capitalization of $19.44 million. The company earns $-7.20 million in net income (profit) each year or ($0.56) on an earnings per share basis.

How many employees does Hoth Therapeutics have?

Hoth Therapeutics employs 4 workers across the globe.

What is Hoth Therapeutics' official website?

The official website for Hoth Therapeutics is www.hoththerapeutics.com.

Where are Hoth Therapeutics' headquarters?

Hoth Therapeutics is headquartered at 1 Rockefeller Plaza Suite 1039, New York NY, 10020.

How can I contact Hoth Therapeutics?

Hoth Therapeutics' mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company can be reached via phone at (646) 756-2997 or via email at [email protected].